| Project Detail |
The operation aims at increasing the manufacturing capacity of Active Pharmaceutical Ingredients (APIs) in Africa. An allocation of up to USD 12 million from the COVID-19 ESSENTIAL API MANUFACTURING IN AFRICA (2020-0584) Global Authorisation is provided to a local manufacturer in Nigeria, supporting the expansion of its facilities to produce several different APIs, which will be used in treatments against malaria.
Objectives
The operation aims at establishing the first manufacturing plant of active pharmaceutical ingredients (APIs) in Nigeria, for use in the production of antimalarial drugs. The objectives are to improve the availability and security of pharmaceutical products in Nigeria and the West Africa region, to increase the robustness of the pharmaceutical supply chain by reducing dependency on imports and to display the regions capacity to integrate backwards in the pharmaceutical manufacturing chain. Furthermore, the increased security and availability of antimalarial drugs is expected to positively contribute towards preventing and treating malaria, which still represents a significant public health threat, notably in Nigeria. |
